The estimated Net Worth of Lynda Sarah Cranston is at least $3.14 Mille dollars as of 26 June 2017. Lynda Cranston owns over 2,083 units of DelMar Pharmaceuticals stock worth over $3,141 and over the last 9 years Lynda sold DMPI stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lynda Cranston DMPI stock SEC Form 4 insiders trading
Lynda has made over 1 trades of the DelMar Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Lynda bought 2,083 units of DMPI stock worth $7,499 on 26 June 2017.
The largest trade Lynda's ever made was buying 2,083 units of DelMar Pharmaceuticals stock on 26 June 2017 worth over $7,499. On average, Lynda trades about 91 units every 0 days since 2016. As of 26 June 2017 Lynda still owns at least 2,344 units of DelMar Pharmaceuticals stock.
You can see the complete history of Lynda Cranston stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Lynda Cranston's mailing address?
Lynda's mailing address filed with the SEC is 12707 HIGH BLUFF DR., SUITE 200, SAN DIEGO, CA, 92130.
Insiders trading at DelMar Pharmaceuticals
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman e Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
What does DelMar Pharmaceuticals do?
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
What does DelMar Pharmaceuticals's logo look like?
Complete history of Lynda Cranston stock trades at DelMar Pharmaceuticals
DelMar Pharmaceuticals executives and stock owners
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Saiid Zarrabian,
President, Chief Executive Officer, Director -
Scott Praill,
Chief Financial Officer -
Dennis Brown,
Chief Scientific Officer -
Robert Hoffman,
Independent Chairman of the Board -
Robert Toth,
Independent Director -
Keith Murphy,
Director -
John Liatos,
Director -
Erich Mohr,
Director -
Napoleone Ferrara,
Director -
John K Bell,
Director -
Lynda Sarah Cranston,
Director -
William J Garner,
Director -
Jeffrey Bacha,
Chief Executive Officer